An analytically characterized bovine brain product defined by a 2023 manufacturing patent. Its molecular distribution and process are specific to this disclosure.
Research background
An analytically characterized bovine brain product defined by a 2023 manufacturing patent. Its molecular distribution and process are specific to this disclosure.
What the studies found
The linked records do not yet support a study-level summary for this preparation. Original publications require verification; additional research may exist.
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH
Understanding the evidence
Human research
Human effects are unverified.
Study methods
Manufacturing examples and characterization assays.
Independent replication
Independent replication is not established in the linked sources.
Source access
Original sources and the exact review scope are linked below.
Safety evidence
The linked experiments do not establish a safe human performance regimen.
Open a topic for the evidence assessment.
More findings, background and historyEVIDENCE REVIEW / 6 OCTOBER 2026
Outstanding review questions
Recover and appraise original experiments behind the review, patent or bibliographic trail.
No human intervention report has been identified among the linked records; unclassified archival leads may remain. Publication records can share participants. Source counts are not trial counts.
These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.
2023 · RU2801151C1 · RU2801151C1: Bovine brain protein–polypeptide hydrolysate processManufacturing · 160 rats, four arms of 40. No adverse change in measured behavior, blood biochemistry or organ pathology was described.
Reported findings
Bovine brain hydrolysate manufacturing process with analytical and yeast-growth checks.
Ninety-day rat tolerability series
160 rats, four arms of 40. No adverse change in measured behavior, blood biochemistry or organ pathology was described.Daily intramuscular 1.5, 15 or 150 mg/kg versus water control. Applicant-reported toxicology; underlying tables were not recovered.
Reported final protein–polypeptide concentration
1.0–2.0 mg/mLPreparation concentration, not a human dose.
2023 · RU2801151C1: Bovine brain protein–polypeptide hydrolysate process — RU2801151C1Ninety-day rat tolerability series: 160 rats, four arms of 40. No adverse change in measured behavior, blood biochemistry or organ pathology was described.
2023Patent / reported experimentsFull text available
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
N. V. Fedota, A. N. Shulunova, A. N. Kvochko · RU2801151C1 · patent family RU2801151C1
Bovine brain hydrolysate manufacturing process with analytical and yeast-growth checks.
Findings, study figures and available tables
Reported patent results
Reported findings
Bovine brain hydrolysate manufacturing process with analytical and yeast-growth checks.
Applicant manufacturing examples and gel chromatography. The filing cites Cerebrolysat prior art.
Reported findings and study figures · Original patent, selected methods and examples checked
Measure
Result
Comparison, timing and statistics
Ninety-day rat tolerability series
160 rats, four arms of 40. No adverse change in measured behavior, blood biochemistry or organ pathology was described.
Daily intramuscular 1.5, 15 or 150 mg/kg versus water control. Applicant-reported toxicology; underlying tables were not recovered.
Reported final protein–polypeptide concentration
1.0–2.0 mg/mL
Preparation concentration, not a human dose.
Gel chromatographic characterization
Four fractions, reported 0.5–200 kDa range
Applicant analytical results.
Bioassay
Yeast-growth criterion at least 20% versus control
An assay threshold, not a measured human effect.
A distinct patent-defined preparation. No verified equivalence to Cerebrolysat, Cortexin, PPC-M or PPK-V.
Applicant manufacturing examples and gel chromatography. The filing cites Cerebrolysat prior art.
What was checked
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Limitations & review scope
A distinct patent-defined preparation. No verified equivalence to Cerebrolysat, Cortexin, PPC-M or PPK-V.
A distinct patent-defined preparation. No verified equivalence to Cerebrolysat, Cortexin, PPC-M or PPK-V.
Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Source checked 2026-11-09. See the review scope above for the material assessed.